文献速递肝病消化道肿瘤与早癌

索拉非尼序贯瑞戈非尼治疗肝细胞癌的结局:III期RESORCE试验的补充分析

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
PubMed 文献 · J Hepatol · 2018-04-26

RESORCE试验显示瑞戈非尼可改善索拉非尼治疗进展后肝细胞癌患者的总生存(HR 0.62,95%CI 0.50-0.78;p<0.0001)。本探索性分析按末次索拉非尼剂量及既往索拉非尼治疗至进展时间分层,评估序贯治疗的疗效与安全性,结果显示瑞戈非尼的临床获益不受末次索拉非尼剂量或既往进展速度影响。

要点

  • 按末次索拉非尼剂量分层,瑞戈非尼对比安慰剂的总生存HR相似(800 mg/天为0.67;<800 mg/天为0.68)。
  • 瑞戈非尼组3、4、5级不良事件率按末次索拉非尼剂量800 mg/天 vs <800 mg/天分别为52%、11%、15% vs 60%、10%、12%。
  • 按既往索拉非尼治疗至进展时间四分位分层,瑞戈非尼对比安慰剂的至进展HR分别为0.66、0.26、0.40和0.54。

核心结论

  • 这些探索性分析显示,无论末次索拉非尼剂量或既往索拉非尼治疗至进展时间如何,瑞戈非尼均带来临床获益。
  • 不良事件发生率按末次索拉非尼剂量总体相似。

研究设计与样本

  • RESORCE为III期随机对照试验,573例患者按2:1随机分配至瑞戈非尼160 mg/天(用药3周停1周)或安慰剂组。
  • 本分析为探索性分析,按末次索拉非尼剂量评估疗效与安全性,并评估从索拉非尼开始至死亡的时间。
  • RESORCE中的至进展时间按既往索拉非尼治疗期间的至进展时间进行分析。

主要发现

  • 按末次索拉非尼剂量分层,瑞戈非尼对比安慰剂的总生存HR相似(800 mg/天为0.67;<800 mg/天为0.68)。
  • 瑞戈非尼组3、4、5级不良事件率按末次索拉非尼剂量800 mg/天 vs <800 mg/天分别为52%、11%、15% vs 60%、10%、12%。
  • 从索拉非尼开始至死亡的中位时间(95%CI)瑞戈非尼组为26.0个月(22.6-28.1),安慰剂组为19.2个月(16.3-22.8)。
  • 从索拉非尼开始至索拉非尼治疗进展的中位时间瑞戈非尼组为7.2个月,安慰剂组为7.1个月。
  • 按既往索拉非尼治疗至进展时间四分位(Q)分层,瑞戈非尼对比安慰剂的至进展HR(95%CI)分别为Q1 0.66(0.45-0.96)、Q2 0.26(0.17-0.40)、Q3 0.40(0.27-0.60)、Q4 0.54(0.36-0.81)。

临床怎么用

  • 作者认为,索拉非尼序贯瑞戈非尼治疗肝细胞癌可能延长生存,超出既往报告。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The RESORCE trial showed that regorafenib improves overall survival (OS) in patients with hepatocellular carcinoma progressing during sorafenib treatment (hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.50-0.78; p <0.0001). This exploratory analysis describes outcomes of sequential treatment with sorafenib followed by regorafenib. METHODS: In RESORCE, 573 patients were randomized 2:1 to regorafenib 160 mg/day or placebo for 3 weeks on/1 week off. Efficacy and safety were evaluated by last sorafenib dose. The time from the start of sorafenib to death was assessed. Time to progression (TTP) in RESORCE was analyzed by TTP during prior sorafenib treatment. RESULTS: HRs (regorafenib/placebo) for OS by last sorafenib dose were similar (0.67 for 800 mg/day; 0.68 for <800 mg/day). Rates of grade 3, 4, and 5 adverse events with regorafenib by last sorafenib dose (800 mg/day vs. <800 mg/day) were 52%, 11%, and 15% vs. 60%, 10%, and 12%, respectively. Median times (95% CI) from the start of sorafenib to death were 26.0 months (22.6-28.1) for regorafenib and 19.2 months (16.3-22.8) for placebo. Median time from the start of sorafenib to progression on sorafenib was 7.2 months for the regorafenib arm and 7.1 months for the placebo arm. An analysis of TTP in RESORCE in subgroups defined by TTP during prior sorafenib in quartiles (Q) showed HRs (regorafenib/placebo; 95% CI) of 0.66 (0.45-0.96; Q1); 0.26 (0.17-0.40; Q2); 0.40 (0.27-0.60; Q3); and 0.54 (0.36-0.81; Q4). CONCLUSIONS: These exploratory analyses show that regorafenib conferred a clinical benefit regardless of the last sorafenib dose or TTP on prior sorafenib. Rates of adverse events were generally similar regardless of the last sorafenib dose. LAY SUMMARY: This analysis examined characteristics and outcomes of patients with hepatocellular carcinoma who were treated with regorafenib after they had disease progression during sorafenib treatment. Regorafenib provided clinical benefit to patients regardless of the pace of their disease progression during prior sorafenib treatment and regardless of their last sorafenib dose. The sequence of sorafenib followed by regorafenib for hepatocellular carcinoma may extend survival beyond what has been previously reported. ClinicalTrials.gov NCT01774344.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Finn RS, Merle P, Granito A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018. PMID: 29704513. doi:10.1016/j.jhep.2018.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。